JPMorgan Chase & Co. lowered its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 2.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,636 shares of the biotechnology company’s stock after selling 1,619 shares during the period. JPMorgan Chase & Co. owned approximately 0.12% of bluebird bio worth $7,571,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BLUE. QS Investors LLC raised its position in shares of bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares during the period. Bank of Montreal Can raised its position in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares during the period. Biondo Investment Advisors LLC bought a new stake in shares of bluebird bio in the third quarter valued at approximately $203,000. SG Americas Securities LLC raised its position in shares of bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 295 shares during the period. Finally, Fairfield Bush & CO. bought a new stake in shares of bluebird bio in the second quarter valued at approximately $210,000.

BLUE has been the topic of a number of analyst reports. Maxim Group reaffirmed a “buy” rating and set a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a report on Monday, October 9th. Barclays initiated coverage on shares of bluebird bio in a report on Wednesday, September 6th. They set an “overweight” rating and a $151.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $135.00 target price (up previously from $121.00) on shares of bluebird bio in a report on Friday, September 1st. Leerink Swann reaffirmed an “outperform” rating and set a $162.00 target price (up previously from $145.00) on shares of bluebird bio in a report on Wednesday, November 1st. Finally, BMO Capital Markets upped their target price on shares of bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a report on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the stock. bluebird bio has a consensus rating of “Hold” and an average target price of $157.45.

Shares of bluebird bio, Inc. (NASDAQ BLUE) opened at $181.10 on Wednesday. bluebird bio, Inc. has a 12 month low of $60.95 and a 12 month high of $222.03. The stock has a market cap of $8,803.03, a price-to-earnings ratio of -25.80 and a beta of 2.08.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same period last year, the company posted ($2.07) EPS. bluebird bio’s revenue for the quarter was up 397.4% on a year-over-year basis. analysts predict that bluebird bio, Inc. will post -6.72 earnings per share for the current year.

In other news, COO Susanna Gatti High sold 1,282 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $172.15, for a total value of $220,696.30. Following the completion of the sale, the chief operating officer now owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Philip D. Gregory sold 2,250 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $172.54, for a total transaction of $388,215.00. Following the completion of the sale, the insider now directly owns 28,734 shares of the company’s stock, valued at approximately $4,957,764.36. The disclosure for this sale can be found here. Insiders sold a total of 215,082 shares of company stock valued at $37,227,332 in the last ninety days. 3.90% of the stock is owned by corporate insiders.

WARNING: “JPMorgan Chase & Co. Lowers Stake in bluebird bio, Inc. (BLUE)” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://theolympiareport.com/2017/12/27/jpmorgan-chase-co-lowers-stake-in-bluebird-bio-inc-blue-2.html.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.